Jacob Hooker
Scientific Advisor Rocket Science Health
Seminars
Thursday 21st May 2026
Device Technology Should Be Your First Decision, Not Your Last Intranasal drug development programs carry tens of millions in R&D investment and hundreds of millions in sales potential
10:00 am
- Device selection is often a late-stage decision—long after the critical specifications that determine scientific success, commercial viability, and patient experience have been locked in.
- The Rocket Science Health session will give you a front row seat to a live demonstration of novel IN device technology to highlight the importance of early device selection. We will show you how the combination of patented fluidics and human factors-centered design enables precise, repeatable drug deposition to the upper regions of the nasal cavity.
- Walk away from our session knowing why device technology should be considered early in the R&D process and which specifications are most critical to your program’s success.
